Organic Letters, volume 6, issue 17, pages 2901-2904
Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans
Anne-Marie Faucher
1
,
Murray D. Bailey
1
,
Pierre L Beaulieu
1
,
Christian Brochu
1
,
Jean-Simon Duceppe
1
,
Jean-Marie Ferland
1
,
Elise Ghiro
1
,
Vida Gorys
1
,
Ted Halmos
1
,
Stephen H Kawai
1
,
Martin Poirier
1
,
Bruno Simoneau
1
,
CHARLES A. COLE
1
,
Montse Llinas-Brunet
1
1
Chemistry Department, Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval, (Québec) Canada H7S 2G5
|
Publication type: Journal Article
Publication date: 2004-07-21
Journal:
Organic Letters
scimago Q1
wos Q1
SJR: 1.245
CiteScore: 9.3
Impact factor: 4.9
ISSN: 15237060, 15237052
PubMed ID:
15330643
Organic Chemistry
Biochemistry
Physical and Theoretical Chemistry
Abstract
The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.
Found
Found
Top-30
Journals
|
1
2
3
4
5
6
7
8
|
|
|
Organic Process Research and Development
8 publications, 8.16%
|
|
|
Journal of Organic Chemistry
5 publications, 5.1%
|
|
|
Chemical Reviews
5 publications, 5.1%
|
|
|
Organic Letters
5 publications, 5.1%
|
|
|
Journal of Organometallic Chemistry
4 publications, 4.08%
|
|
|
Journal of Medicinal Chemistry
4 publications, 4.08%
|
|
|
Bioorganic and Medicinal Chemistry
3 publications, 3.06%
|
|
|
Bioorganic and Medicinal Chemistry Letters
3 publications, 3.06%
|
|
|
Antimicrobial Agents and Chemotherapy
3 publications, 3.06%
|
|
|
Tetrahedron
2 publications, 2.04%
|
|
|
Angewandte Chemie - International Edition
2 publications, 2.04%
|
|
|
Angewandte Chemie
2 publications, 2.04%
|
|
|
European Journal of Organic Chemistry
2 publications, 2.04%
|
|
|
Chemistry - A European Journal
2 publications, 2.04%
|
|
|
Advanced Synthesis and Catalysis
2 publications, 2.04%
|
|
|
Topics in Heterocyclic Chemistry
2 publications, 2.04%
|
|
|
Beilstein Journal of Organic Chemistry
1 publication, 1.02%
|
|
|
Future Virology
1 publication, 1.02%
|
|
|
Molecules
1 publication, 1.02%
|
|
|
Applied Biochemistry and Biotechnology
1 publication, 1.02%
|
|
|
Journal of Gastroenterology
1 publication, 1.02%
|
|
|
Acta Pharmacologica Sinica
1 publication, 1.02%
|
|
|
Science
1 publication, 1.02%
|
|
|
Bioorganic Chemistry
1 publication, 1.02%
|
|
|
Antiviral Research
1 publication, 1.02%
|
|
|
Journal of Hepatology
1 publication, 1.02%
|
|
|
Journal of Biological Chemistry
1 publication, 1.02%
|
|
|
Drug Discovery Today
1 publication, 1.02%
|
|
|
Coordination Chemistry Reviews
1 publication, 1.02%
|
|
|
1
2
3
4
5
6
7
8
|
Publishers
|
5
10
15
20
25
30
|
|
|
American Chemical Society (ACS)
28 publications, 28.57%
|
|
|
Wiley
26 publications, 26.53%
|
|
|
Elsevier
22 publications, 22.45%
|
|
|
Springer Nature
7 publications, 7.14%
|
|
|
American Society for Microbiology
3 publications, 3.06%
|
|
|
MDPI
2 publications, 2.04%
|
|
|
Beilstein-Institut
1 publication, 1.02%
|
|
|
Taylor & Francis
1 publication, 1.02%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 1.02%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 1.02%
|
|
|
Georg Thieme Verlag KG
1 publication, 1.02%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 1.02%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Faucher A. et al. Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans // Organic Letters. 2004. Vol. 6. No. 17. pp. 2901-2904.
GOST all authors (up to 50)
Copy
Faucher A., Bailey M. D., Beaulieu P. L., Brochu C., Duceppe J., Ferland J., Ghiro E., Gorys V., Halmos T., Kawai S. H., Poirier M., Simoneau B., COLE C., Llinas-Brunet M. Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans // Organic Letters. 2004. Vol. 6. No. 17. pp. 2901-2904.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1021/ol0489907
UR - https://doi.org/10.1021/ol0489907
TI - Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans
T2 - Organic Letters
AU - Faucher, Anne-Marie
AU - Bailey, Murray D.
AU - Beaulieu, Pierre L
AU - Brochu, Christian
AU - Duceppe, Jean-Simon
AU - Ferland, Jean-Marie
AU - Ghiro, Elise
AU - Gorys, Vida
AU - Halmos, Ted
AU - Kawai, Stephen H
AU - Poirier, Martin
AU - Simoneau, Bruno
AU - COLE, CHARLES A.
AU - Llinas-Brunet, Montse
PY - 2004
DA - 2004/07/21
PB - American Chemical Society (ACS)
SP - 2901-2904
IS - 17
VL - 6
PMID - 15330643
SN - 1523-7060
SN - 1523-7052
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2004_Faucher,
author = {Anne-Marie Faucher and Murray D. Bailey and Pierre L Beaulieu and Christian Brochu and Jean-Simon Duceppe and Jean-Marie Ferland and Elise Ghiro and Vida Gorys and Ted Halmos and Stephen H Kawai and Martin Poirier and Bruno Simoneau and CHARLES A. COLE and Montse Llinas-Brunet},
title = {Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans},
journal = {Organic Letters},
year = {2004},
volume = {6},
publisher = {American Chemical Society (ACS)},
month = {jul},
url = {https://doi.org/10.1021/ol0489907},
number = {17},
pages = {2901--2904},
doi = {10.1021/ol0489907}
}
Cite this
MLA
Copy
Faucher, Anne-Marie, et al. “Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans.” Organic Letters, vol. 6, no. 17, Jul. 2004, pp. 2901-2904. https://doi.org/10.1021/ol0489907.